These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15854546)

  • 1. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
    Meng FY; Fu YB
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibody therapy for acute leukemia].
    Takeshita A
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic monoclonal antibodies in onco-hematology].
    Cartron G; Rossi JF
    Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for acute leukemias.
    Caron PC; Scheinberg DA
    Curr Opin Oncol; 1994 Jan; 6(1):14-22. PubMed ID: 8204688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
    Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
    Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
    [No Abstract]   [Full Text] [Related]  

  • 7. [Monoclonal antibody therapies for acute leukemia].
    Takeshita A; Ono R
    Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
    Cheung KC; Wong LG; Yeung YM
    Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
    [No Abstract]   [Full Text] [Related]  

  • 9. [Monoclonal antibody therapy and laboratory medicine].
    Takeshita A
    Rinsho Byori; 2004 Nov; 52(11):917-23. PubMed ID: 15658471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
    Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
    Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
    [No Abstract]   [Full Text] [Related]  

  • 11. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
    Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R
    Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibody directed therapy for leukemia].
    Takeshita A; Naito K; Ohno R
    Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 15. New developments in the treatment of acute myeloid leukemia.
    Radich J; Sievers E
    Oncology (Williston Park); 2000 Nov; 14(11A):125-31. PubMed ID: 11195406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
    Wong ET
    Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
    Gibson AD
    Clin Lymphoma; 2002 Jun; 3(1):18-9. PubMed ID: 12141950
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibody therapy of APL.
    Maslak PG; Jurcic JG; Scheinberg DA
    Curr Top Microbiol Immunol; 2007; 313():205-19. PubMed ID: 17217045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia.
    Cotter M; Rooney S; O'Marcaigh A; Smith OP
    Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.